Manufacturer record
Skylink Pharma: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Skylink Pharma (Gujarat) was declared Not of Standard Quality in June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: SL25156, Paracetamol Paediatric Oral Suspension IP 250mg, 60ml (exp Feb 2028). CDTL, Mumbai (CDSCO lab) found it not of standard quality: The sample does not conform to as per I.P. 2022 with respect to the test of Microbial contamination (Total aerobic viable count). Listed in the June 2026 alert.
Records by type
1 record linked to Skylink Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Paracetamol Paediatric Oral Suspension IP 250mg, 60ml | Batch SL25156Mfg Mar 2026 · Exp Feb 2028 | The sample does not conform to as per I.P. 2022 with respect to the test of Microbial contamination (Total aerobic viable count).Microbial limits | CDTL, MumbaiCDSCO lab | Jun 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.